


# Giovanni Caforio, M.D.

Nationality: Italian/American | Year of birth: 1964



Giovanni Caforio has had an international career in the healthcare industry spanning more than 35 years. He graduated in medicine and surgery in Italy in 1988, and has held senior leadership positions at Abbott Laboratories and Bristol Myers Squibb (BMS) in several European countries and the US. He was CEO of BMS from 2015 to 2023 and Chair of the company's board of directors from 2017 to 2024. Under his leadership, BMS nearly tripled its revenue, undertook several strategic acquisitions and partnerships, and launched 12 new medicines. Giovanni Caforio currently serves on the board of Stryker Corp. He is fluent in Italian, French, Spanish, Portuguese and English. He is independent from Novartis according to the independence criteria

set forth by the Board of Directors.

## Professional experience

- Chair of the board of directors, BMS, US (2017-2024)
- Chief Executive Officer, BMS, US (2015-2023)
- Chief Operating Officer, BMS, US (2014-2015)
- Executive Vice President, Chief Commercial Officer, BMS, US (2013-2014)
- President, US Pharmaceuticals, BMS, US (2011-2013)
- Various managerial positions at BMS and Abbot Laboratories in the US, France, Italy, Portugal and Spain (1990-2011)

## Mandates

### Current:

- Board member, Stryker Corp, US

### Past:

- Chair, board of directors, PhRMA (2019-2020)

## Education

- Doctor of medicine and surgery, Sapienza University, Rome, Italy

## Key skills

- Medicine/healthcare/R&D
- Environmental, social and governance (ESG)
- Leadership/management
- Law/regulatory/risk management